Late onset of new conduction disturbances requiring permanent pacemaker implantation following TAVI.
Nynke H M Kooistra, Martijn S van Mourik, Ramón Rodríguez-Olivares...
https://pubmed.ncbi.nlm.nih.gov/32005676/Actively Recruiting
Led by Hospital Universitari Vall d'Hebron Research Institute · Updated on 2026-07-22
100
Participants Needed
1
Research Sites
4 weeks
Total Duration
This research aims to evaluate the effectiveness and safety of a non-invasive electrocardiographic monitoring strategy combined with early discharge in patients who have conduction disorders following transfemoral or transaortic transcatheter aortic valve implantation TAVI for severe aortic stenosis. The study compares this approach to standard care to understand its potential benefits. Patients included have specific conduction disorders and are clinically stable 24 hours after the TAVI procedure. Participants are randomly assigned to one of two groups. One group is discharged from the hospital 24 hours after TAVI with the PhysioMem PM 100 4G ambulatory monitoring device to track heart conduction remotely. The other group follows the usual discharge procedures under standard care. The study measures outcomes over 30 days and up to 12 months, including death rates, rehospitalizations, heart rhythm events, and quality of life. During the study, participants undergo monitoring of heart rhythm events and clinical status, including remote electrocardiographic assessments. The research team tracks events such as arrhythmias requiring therapy changes, pacemaker implantation, and hospital readmissions. Quality of life is assessed with questionnaires, and data on hospital stay lengths and costs are collected. The total study participation lasts up to 12 months with follow-up evaluations to observe both short- and long-term effects.
CONDITIONS
Pilot Study to Evaluate a Noninvasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With Conduction Disorders Following TAVI Implantation (IMPROVE Study)
B
Bruno García del Blanco, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hospital Universitari Vall d'Hebron Research Institute
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 12 months
Participants are randomly assigned to either early discharge with a wearable heart monitoring device or discharge according to standard care.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Nynke H M Kooistra, Martijn S van Mourik, Ramón Rodríguez-Olivares...
https://pubmed.ncbi.nlm.nih.gov/32005676/Melissa Tsoi, Kanul Tandon, Peter J Zimetbaum...
https://pubmed.ncbi.nlm.nih.gov/34132653/Michał Szotek, Łukasz Drużbicki, Karol Sabatowski...
https://pubmed.ncbi.nlm.nih.gov/37762995/Nicolo Piazza, Rutger-Jan Nuis, Apostolos Tzikas...
https://pubmed.ncbi.nlm.nih.gov/20884435/Antonio Mangieri, Claudio Montalto, Matteo Pagnesi...
https://pubmed.ncbi.nlm.nih.gov/30018969/Lennart van Gils, Sara Baart, Herbert Kroon...
https://pubmed.ncbi.nlm.nih.gov/29688322/Hospital Universitari Vall d'Hebron Research Institute
Lead Sponsor